The specter of generic challenges has long loomed over copyright’s iconic drug, Viagra, sparking questions about the outlook of connected medicinal ventures. While first times saw substantial profits, the patent expiration has allowed the path for cheaper alternatives, likely diminishing profitability and presenting a real risk for investors look